Mark Benedyk, PhD, President and Chief Executive Officer
Dr. Benedyk has over 20 years of experience as a business development executive and consultant to life science companies. He previously headed The Pfizer Incubator (TPI) in La Jolla, CA where he held board positions with TPI and its portfolio companies, reviewed investment opportunities for the Incubator, and oversaw the TPI operations team. Before that, he held executive positions in Business Development and Intellectual Property at Ascenta Therapeutics, Optimer Pharmaceuticals (now Merck (NYSE: MRK)), Aurora Biosciences (now Vertex (NASDAQ: VRTX)) and Elan Pharmaceuticals (now Perrigo (NYSE: PRGO)). In addition, Dr. Benedyk founded and managed Rila Partners LLC, a life sciences strategy and business development advisory firm serving specialty care biotechnology companies. He currently serves on the board of Canada’s Accel-Rx Health Sciences Accelerator and is a Strategic Advisor to KemPharm (NASDAQ: KMPH). His transaction experience totals more than $800 MM and he has been involved in capital raises of $150+ MM in past financings. Dr. Benedyk received a PhD in Developmental Genetics from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. He received his BS in Microbiology and Botany from the University of Michigan.
Lynne Rollins, MBA, Chief Financial Officer
Ms. Rollins brings to Telephus Medical more than 30 years of experience in healthcare-related finance and business development. She has served as CFO at a number of start-up pharmaceutical and medical device companies, including Sonexa Therapeutics, Calixa Therapeutics, Tensys Medical, Inspiration Biopharmaceuticals, Syndax Pharmaceuticals, Orexigen Therapeutics, Novalar Pharmaceuticals, and Novacea. Ms. Rollins also held executive roles in Finance at Ascenta Therapeutics and, earlier in her career, within Baxter Healthcare’s cardiopulmonary business. She also currently serves as CFO for Domain Russia Investments, a partnership of the venture capital firm Domain Associates designed to foster innovation in the Russian health sciences sector. Ms. Rollins received her BS in Finance from California State University and her MBA from Pepperdine University.
Robert Geckeler, MBA, Vice President Operations
Mr. Geckeler has 25 years of pharmaceutical industry experience spanning a wide range of therapeutic areas and product formats. He has managed and led product development programs at all stages, from proof-of-concept to registration and launch, as well as life-cycle management for a number of marketed therapeutics. Mr. Geckeler previously served as VP of Development at Xenome Ltd., where he had broad responsibility for global operations supporting clinical-stage product development, was team leader for the company’s most advanced therapeutic program, and represented the company on multiple, early-stage research collaborations. Before that, he held executive and project leadership positions at Elan Pharmaceuticals, Arena Pharmaceuticals, Avera Pharmaceuticals, and PAREXEL International. Mr. Geckeler holds a BA in Biology from Washington University in St. Louis, and an MBA from San Diego State University.
Caryn Peterson, Vice President Clinical & Regulatory Affairs
Ms. Peterson has over 30 years of pharmaceutical industry experience, and possesses significant strengths in US and ex-US regulatory affairs strategy. She is Founder and General Partner of DSC Associates, who provide regulatory and clinical strategy consulting services to the pharmaceutical, biotechnology and medical device industries. Ms. Peterson previously served as VP of Regulatory Affairs at FeRx, and held senior managerial positions in Pharmaceutical Development and Regulatory Affairs at Amylin Pharmaceuticals, with additional experience from both the therapeutics and diagnostics divisions at Hybritech Incorporated.
Barry Rosenblatt, PhD, Vice President Manufacturing
Dr. Rosenblatt is an expert in the chemistry and manufacturing controls (CMC) of biotherapeutics. His nearly 30 years of experience at Centocor, Johnson and Johnson, and Charles River Laboratories includes the design and implementation of CMC programs for a number of highly successful, marketed monoclonal antibody products. In addition to leading the process development programs for these products and others, he was instrumental in the preparation of the CMC sections for the respective Biologics License Applications leading to their approval. Since 2004, he has served as President of SME Biotech Consulting. Dr. Rosenblatt holds a PhD in Cell Biology and Immunology from the Albert Einstein College of Medicine, and a BA in Biochemistry from Columbia University.